This HTML5 document contains 46 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n17http://localhost/temp/predkladatel/
n16http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n7http://linked.opendata.cz/ontology/domain/vavai/
shttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
n3http://linked.opendata.cz/ontology/domain/vavai/riv/
n5http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F61989592%3A15110%2F08%3A00007569%21RIV09-MSM-15110___/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n9http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n15http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n12http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n8http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n14http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n13http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n11http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F61989592%3A15110%2F08%3A00007569%21RIV09-MSM-15110___
rdf:type
n7:Vysledek skos:Concept
dcterms:description
This retrospoective subgroup analysis suggests that the dose od IFN can be reduced to manager side-effects while maintaining efficacy in patiens with mrcci recweiving bevacizumat + IFN Popsán efekt redukce dávky interferonu na účinnost v kombinaci s bevacizumabem u karcinomu ledviny This retrospoective subgroup analysis suggests that the dose od IFN can be reduced to manager side-effects while maintaining efficacy in patiens with mrcci recweiving bevacizumat + IFN
dcterms:title
První linie bevacizumabu v kombinaci s redukovanou dávkou interferonu-α2a je aktivní u pacientů s karcinomem ledviny First-line bevacizumab combined with reduced dose interferon-2a is active in patients with metastatic renal cell carcinoma First-line bevacizumab combined with reduced dose interferon-2a is active in patients with metastatic renal cell carcinoma
skos:prefLabel
První linie bevacizumabu v kombinaci s redukovanou dávkou interferonu-α2a je aktivní u pacientů s karcinomem ledviny First-line bevacizumab combined with reduced dose interferon-2a is active in patients with metastatic renal cell carcinoma First-line bevacizumab combined with reduced dose interferon-2a is active in patients with metastatic renal cell carcinoma
skos:notation
RIV/61989592:15110/08:00007569!RIV09-MSM-15110___
n3:aktivita
n12:S
n3:aktivity
S
n3:cisloPeriodika
8
n3:dodaniDat
n11:2009
n3:domaciTvurceVysledku
n16:5290791
n3:druhVysledku
n14:J
n3:duvernostUdaju
n15:S
n3:entitaPredkladatele
n5:predkladatel
n3:idSjednocenehoVysledku
368120
n3:idVysledku
RIV/61989592:15110/08:00007569
n3:jazykVysledku
n8:eng
n3:klicovaSlova
Antiangiogenic therapy; bevacizumab; interferon-α; renal cell carcinoma; vascular endothelial growth
n3:klicoveSlovo
n9:vascular%20endothelial%20growth n9:interferon-%CE%B1 n9:renal%20cell%20carcinoma n9:bevacizumab n9:Antiangiogenic%20therapy
n3:kodStatuVydavatele
GB - Spojené království Velké Británie a Severního Irska
n3:kontrolniKodProRIV
[A5E5CE69CBC8]
n3:nazevZdroje
Annals of Oncology
n3:obor
n13:FD
n3:pocetDomacichTvurcuVysledku
1
n3:pocetTvurcuVysledku
6
n3:rokUplatneniVysledku
n11:2008
n3:svazekPeriodika
19
n3:tvurceVysledku
Koralewski, P. Revaud, A. Bracarda, S. Pluzanska, A. Melichar, Bohuslav Szczyylik, C.
s:issn
0923-7534
s:numberOfPages
7
n17:organizacniJednotka
15110